2026-10-29 22:50:44 UTC#541564newconfirmednews
Biogen (BIIB) stock news
Biogen (BIIB) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 21:55:55 UTC#541305newconfirmednews
Canaccord Genuity maintains Biogen at Buy, raises price target to $272 from $248
2026-10-29 21:44:00 UTC#541203newconfirmednews
Argus Research sets Biogen price target at $280.00 per share
2026-10-29 19:19:25 UTC#540150newconfirmednews
RBC Capital maintains Biogen at Outperform, raises price target to $272 from $256
2026-10-29 17:28:44 UTC#539400newconfirmednews
Morgan Stanley maintains Biogen at Equal-Weight, raises price target to $238 from $231
2026-10-29 16:18:24 UTC#539007newconfirmednews
UBS maintains Biogen at Buy, raises price target to $300 from $270
2026-10-29 16:13:00 UTC#538917newconfirmednews
TD Cowen maintains Buy rating on Biogen
2026-10-29 14:48:00 UTC#538366newconfirmednews
Truist Securities raises Biogen price target to $260 from $235
2026-10-29 14:42:46 UTC#538291newconfirmednews
Wedbush maintains Biogen at Neutral, raises price target to $225 from $212
2026-10-29 13:47:55 UTC#537903newconfirmednews
Wells Fargo upgrades eBay to Equal Weight, Deutsche Bank upgrades PDD to Buy, Argus upgrades Biogen to Buy
2026-10-29 11:09:20 UTC#536566newconfirmedpress release
Biogen to present long-term data for Lecanemab and Diranersen at CTAD 2026 conference
2026-10-28 19:20:00 UTC#531707newconfirmednews
Biogen Inc. average analyst price target raised to $251.48 from $248.97, consensus Buy rating maintained
2026-10-28 14:42:13 UTC#529798duplicateconfirmednews
Biogen Q3 revenue rises 11% on growth products and Apellis contribution, FY26 EPS guidance floor raised
2026-10-28 14:29:59 UTC#529749duplicateconfirmednews
Biogen Q3 results beat estimates on rare-disease drug demand, offsetting MS franchise declines
reutersimportance 0.30trust 0.90Biogen Inc. +0.40Apellis Pharmaceuticals, Inc. +0.30Chris Viehbacher +0.20+2 entities
2026-10-28 12:27:02 UTC#528736newconfirmednews
Biogen Inc. Q3 2026 earnings call commences
2026-10-28 12:27:00 UTC#528747duplicateconfirmednews
Biogen Q3 Earnings Beat Estimates as New Growth Drivers Offset Declining MS Franchise
dow_jonesimportance 0.30trust 0.80Biogen Inc. +0.60Apellis Pharmaceuticals, Inc. +0.40Citigroup Inc. +0.20+1 entities
2026-10-28 11:09:00 UTC#528038duplicateconfirmednews
Biogen reports Q3 net loss driven by transaction-related charges
2026-10-28 10:44:48 UTC#527861duplicateconfirmednews
Biogen Q3 EPS $2.62 beats $2.02 estimate, revenue $2.8B exceeds $2.64B; raises FY26 EPS guidance floor
yahooimportance 0.30trust 0.70Biogen Inc. +0.60Apellis Pharmaceuticals, Inc. +0.40SYFOVRE +0.50+1 entities
2026-10-28 10:31:01 UTC#527705duplicateconfirmeddata release
Biogen Q3 2026 reports $2.8B revenue and $20.6M net loss
2026-10-28 10:25:00 UTC#527668newconfirmednews
Eisai reports Q3 2026 global Leqembi sales of 32.2 billion yen
pr newswireimportance 0.40trust 0.90BioArctic AB +0.30Eisai Co., Ltd. +0.30Biogen Inc. +0.30+1 entities